Trial · NCT03806127
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Irritable Bowel Syndrome (IBS) With Predominantly Diarrhea (IBS-D) Participants Who Were Abdominal Pain Intensity (API) Weekly Responders at Week 12 | Placebo | 27 | Participants | ||
| Number of Irritable Bowel Syndrome (IBS) With Predominantly Diarrhea (IBS-D) Participants Who Were Abdominal Pain Intensity (API) Weekly Responders at Week 12 | Vibegron 75 mg | 27 | Participants | ||
| Number of Global Improvement Scale (GIS) Responders at Week 12 for All IBS Participants, Including IBS-D and IBS-M Participants | Placebo | IBS-D Participants | 21 | Participants | |
| Number of Global Improvement Scale (GIS) Responders at Week 12 for All IBS Participants, Including IBS-D and IBS-M Participants | Vibegron 75 mg | IBS-D Participants | 28 | Participants | |
| Number of Global Improvement Scale (GIS) Responders at Week 12 for All IBS Participants, Including IBS-D and IBS-M Participants | Placebo | IBS-M Participants | 16 | Participants | |
| Number of Global Improvement Scale (GIS) Responders at Week 12 for All IBS Participants, Including IBS-D and IBS-M Participants | Vibegron 75 mg | IBS-M Participants | 16 | Participants | |
| Number of Global Improvement Scale (GIS) Responders at Week 12 for All IBS Participants, Including IBS-D and IBS-M Participants | Placebo | All Participants | 37 | Participants | |
| Number of Global Improvement Scale (GIS) Responders at Week 12 for All IBS Participants, Including IBS-D and IBS-M Participants | Vibegron 75 mg | All Participants | 44 | Participants | |
| Number of IBS-D Participants Who Were API Weekly Responders With ≥ 40% Improvement Over 12 Weeks | Placebo | 20 | Participants | ||
| Number of IBS-D Participants Who Were API Weekly Responders With ≥ 40% Improvement Over 12 Weeks | Vibegron 75 mg | 22 | Participants | ||
| Number of IBS-D Participants Who Were API Weekly Responders With ≥ 50% Improvement Over 12 Weeks | Placebo | 13 | Participants | ||
| Number of IBS-D Participants Who Were API Weekly Responders With ≥ 50% Improvement Over 12 Weeks | Vibegron 75 mg | 18 | Participants | ||
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Placebo | 37 | Participants | ||
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Vibegron 75 mg | 37 | Participants | ||
| Number of Participants With Clinically Meaningful Changes From Baseline in Clinical Laboratory Values at Week 12 | Placebo | 0 | Participants | ||
| Number of Participants With Clinically Meaningful Changes From Baseline in Clinical Laboratory Values at Week 12 | Vibegron 75 mg | 0 | Participants | ||
| Number of Participants With Clinically Relevant Changes From Baseline in Vital Sign Values at Week 12 | Placebo | 0 | Participants | ||
| Number of Participants With Clinically Relevant Changes From Baseline in Vital Sign Values at Week 12 | Vibegron 75 mg | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03806127/results